SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-288502
Filing Date
2023-12-04
Accepted
2023-12-04 17:10:53
Documents
13
Period of Report
2023-11-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d595715d8k.htm   iXBRL 8-K 40578
2 EX-10.1 d595715dex101.htm EX-10.1 137002
  Complete submission text file 0001193125-23-288502.txt   342677

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nltx-20231130.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nltx-20231130_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nltx-20231130_pre.xml EX-101.PRE 11265
7 EXTRACTED XBRL INSTANCE DOCUMENT d595715d8k_htm.xml XML 3400
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 231464246
SIC: 2834 Pharmaceutical Preparations